Drugs / LVIVO-TaVec122
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07628582 | Sep 2026 → Oct 2028 expected | B-cell neoplasm | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LVIVO-TaVec122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07628582 ↗ |